Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs

2015 ◽  
Author(s):  
Morten Würtz ◽  
Erik L. Grove
Keyword(s):  
Cardiovascular Disease ◽  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Antiplatelet Drugs

Association of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure

2021 ◽  
Vol 96 (10) ◽  
pp. 2540-2549
Author(s):  
Elizabeth J. Bell ◽  
Suzette J. Bielinski ◽  
Jennifer L. St. Sauver ◽  
Lin Y. Chen ◽  
Mary R. Rooney ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Proton Pump Inhibitors ◽  
Proton Pump

Drug Interactions with Proton Pump Inhibitors

Drug Safety ◽  
1997 ◽  
Vol 16 (3) ◽  
pp. 171-179 ◽  
Author(s):  
Peter Unge ◽  
Tommy Andersson
Keyword(s):  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump

Adverse drug reactions due to drug–drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method

2016 ◽  
Vol 15 (2) ◽  
pp. 223-236 ◽  
Author(s):  
Emre Yucel ◽  
Mesut Sancar ◽  
Aylin Yucel ◽  
Betul Okuyan
Keyword(s):  
Drug Interactions ◽  
Adverse Drug Reactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Systematic Reviews ◽  
Drug Reactions

scholarly journals The Effect of Proton Pump Inhibitors on Possible Drug Interactions and Microbiota

2020 ◽  
Vol 9 (2) ◽  
pp. 197-207
Author(s):  
Fatma Betül İSPİR ◽  
Şaziye Sezin PALABIYIK YÜCELİK ◽  
Terken BAYDAR
Keyword(s):  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump

A Cross-Sectional Study on Single-Day Use of Proton Pump Inhibitors in Tertiary Care Hospitals of South India

2019 ◽  
pp. 001857871987387
Author(s):  
Zabiuddin Ahad M ◽  
Alekhya Lavu ◽  
Maria Ansari ◽  
Raviraj Acharya V ◽  
Rajesh Vilakkathala
Keyword(s):  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
South India ◽  
Tertiary Care ◽  
Cross Sectional Study ◽  
Teaching Hospitals ◽  
Intravenous Route ◽  
Sectional Study ◽  
Cross Sectional

Background: Proton pump inhibitors (PPIs) are the most potent antacids used in clinical practice with greater safety and efficacy. Limited data are available on the usage of PPIs in Indian health-care settings. Our aim was to understand the usage pattern and potential drug interactions with concurrently administered medications employing a single-day cross-sectional study design. Methods: A prospective observational cross-sectional study conducted on a single day, at two tertiary care teaching hospitals in South India. Inpatients of above 18 years of age were included. Case profiles were reviewed and data were collected in predesigned forms and analyzed. Drug interactions were identified using Micromedex and Medscape drug-interaction databases. Results: A total of 797 case profiles screened from both the centers; 714 were prescribed with PPIs. In intensive care units (ICUs), the use of PPIs was highest with 95% of cases getting these drugs. A PPI was seen in about 93% of patients, who had more than or equal to 4 drugs in their prescriptions. Pantoprazole was the mostly prescribed PPI in around 90% of the cases. Around 33% of the PPIs usage was through IV (intravenous) route, and 75% of that use was seen in wards. Around 134 drug interactions were identified, of which 10 were of major severity. Conclusions: Around 90% of inpatients were prescribed with PPIs. Pantoprazole is the most commonly prescribed PPI (90%). The IV administration was seen more in wards than ICUs, and 10 major drug interactions were observed in this single-day study. Careful monitoring is needed to avoid serious drug interactions involving PPIs, and training programs should sensitize the clinicians on the evidence-based use of PPIs.

scholarly journals Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

ESMO Open ◽  
2021 ◽  
Vol 6 (5) ◽  
pp. 100231
Author(s):  
M. Del Re ◽  
C. Omarini ◽  
L. Diodati ◽  
M. Palleschi ◽  
I. Meattini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Outcome ◽  
Drug Interactions ◽  
Cancer Patients ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Metastatic Breast ◽  
Breast Cancer Patients

scholarly journals Pantoprazole-Induced Delirium: Review of a Case and Associated Literature

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Anupriya Razdan ◽  
Ramaswamy Viswanathan ◽  
Alan Tusher
Keyword(s):  
Case Report ◽  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Psychiatric History ◽  
Double Dose ◽  
Geriatric Population ◽  
Antiulcer Agents

Background. Proton pump inhibitors (PPIs) are frequently prescribed antiulcer agents in hospitals and are shown to be safer than H-2 blockers. We present a case report of PPI-induced delirium, regarding which not much has been written in the literature. Case Report. We present a case of a 93-year-old woman with no known past psychiatric history, who was hospitalized for syncope workup and who developed delirium after a double dose of pantoprazole. Discussion. Very few reports of PPI-induced delirium exist in the literature. In this case report, we attempt to highlight the mechanism of PPI induced delirium which in our case was most likely due to the primary effects of PPI and drug-drug interactions. Given the paucity of literature on this topic, we encourage further research into relationship between PPI and delirium and urge caution while using PPIs in geriatric population.

scholarly journals Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections

Reumatismo ◽  
2011 ◽  
Vol 63 (1) ◽  
Author(s):  
A. Laria ◽  
A. Zoli ◽  
E. Gremese ◽  
G.F. Ferraccioli
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Rheumatic Diseases ◽  
Proton Pump ◽  
Bone Fractures

scholarly journals The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications

2019 ◽  
Vol 91 (8) ◽  
pp. 118-126 ◽  
Author(s):  
O D Ostroumova ◽  
A I Kochetkov ◽  
A P Pereverzev ◽  
E V Kravchenko ◽  
A N Kazjulin ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cardiovascular Events ◽  
Cardiovascular Complications ◽  
Inclusion Criteria ◽  
Combined Use ◽  
Meta Analyses ◽  
The Relationship

In the article the problem of the combined use of clopidogrel and various proton pump inhibitors (PPIs) in terms of cardiovascular complications risk and stent thrombosis is considered. The results of meta - analyses and a systematic reviews affecting this issue are represented in detail. The inter - drug interactions mechanisms of various PPIs with clopidogrel based on the characteristics of the metabolism in the liver cytochromes system are discussed. The authors conducted a search, systematization and analysis of studies regarding the association between cardiovascular risk and combined use of individual medications from PPI class with clopidogrel, and these results are presented in the review. Currently available data do not allow to answer the question about the differences between individual PPIs in their impact on the risk of adverse cardiovascular events due to the small number of such studies, design heterogeneity, differences in the inclusion criteria and end points as well as in the rate of administration of individual PPIs.

Sign in / Sign up

Export Citation Format

Share Document